Navigation Links
Global Bioenergies Succeeds in Creating a Bacterial Prototype That Produces Isobutene From Glucose

Global Bioenergies Succeeds in Creating a Bacterial Prototype That Produces Isobutene From... -- EVRY, France, October 6, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Alternative Energies, Gas, Oil & Energy, Green Technology, Biotechnology, Chemical, New Products & Services Click to view news release full screen  

Global Bioenergies Succeeds in Creating a Bacterial Prototype That Produces Isobutene From Glucose


EVRY, France, October 6, 2010 /PRNewswire/ -- Global Bioenergies, located on the Genopole campus at Evry (France), announces the first prototype of its manufacturing process for the biological production of isobutene. It relies on the use of a bacterial strain harboring an artificial metabolic pathway created by the company.

Global Bioenergies announces that it has reached a key milestone in the development of its process for the transformation of renewable resources into gaseous isobutene (also called isobutylene or methylpropene). An initial series of bacterial strains were developed that can produce isobutene by transforming glucose.

Marc Delcourt, co-founder and CEO of the company, states, "We have achieved our goal to bioproduce isobutene in vivo ahead of target. We are now concentrating our efforts on increasing both the rate and scale of fermentation. We plan to carry out pilot plant tests prior to the industrial exploitation of the process. This phase will require new financial investment."

Philippe Marliere, co-founder and designer of the process, adds, "We have taught a bacterium to convert glucose to isobutene through an entirely novel process. The metabolic layout that we established passes by 3-hydroxy-isovalerate (also called 3-hydroxy-3-methylbutyrate). This chemical intermediate, which is absent from natural bacteria is, in turn, enzymatically converted into isobutene in our strains. The process is set up in accordance with the patent application filed in July 2008."

Jean-Marc Paris, professor at the EcoleSuperieure de Physique et de Chimie (Paris Tech) and a member of the Scientific Advisory Board, concludes, "This is the first time that an artificial metabolic pathway, which leads the production of a light olefin from renewable resources, has been designed and assembled in a micro-organism. These results set a precedent for the in-depth changes which the worldwide chemical industry will have to undergo in the 21st century."

Fuels, as well as a variety of polymers, representing a global market of $29b, can be manufactured from isobutene. Global Bioenergies is now focused on repeating this success with other molecules of the light olefin family, such as ethylene and propylene, each one associated with markets greater than $100b.

Press and public relations: - Phone: +33-1-64-98-20-50

SOURCE Global Bioenergies
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ground Zero Pharmaceuticals Announces Expansion of Global Consulting in Somatic Cell Therapies
2. Reportlinker Adds Global Synthetic Biology Industry
3. Reportlinker Adds Global Soft Tissue Allografts Industry
4. Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets
5. BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium
6. Diagenode Releases Two New Epigenetic Monoclonal 5-hmC Antibodies for Quantifying Global Hydroxymethylation
7. Reportlinker Adds Biomarkers: Discovery Techniques and Applications - A Global Market Overview
8. Medix Uses Globalpark to Glean Insights From Over 20,000 Opinion Leaders
9. Chiasma to Present at the UBS Global Life Sciences Conference
10. Seahorse Bioscience to Present at 2010 UBS Global Life Sciences Conference
11. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
Post Your Comments:
(Date:11/30/2015)... 2015 Partnership includes an MPP ... for the u niversity , s ... treatment s cale - up through ... Africa , where licensees based anywhere in the world will have ... --> Africa , where licensees based anywhere in the world ...
(Date:11/30/2015)... /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today ... to its Board of Directors to replace Dr. ... wealth of experience as co-founder of Resverlogix, with expertise in ... --> --> Dr. Wong remarked, "I am ... Zenith,s long standing expertise in epigenetics and the advanced stage ...
(Date:11/30/2015)... Nov. 30, 2015  Champions Oncology, Inc. (CSBR), engaged ... to personalize the development and use of oncology drugs, ... Officer, will be presenting at the LD MICRO Investor ... Standard Time (PST).  The conference, held at the Luxe ... CA , will feature 200 small/micro-cap companies and ...
(Date:11/30/2015)... -- HUYA Bioscience International, the leader in accelerating global development ... announced it has signed a Memorandum of Understanding with ... between KDDF and HUYA with the ultimate goal of ... the global market. China,s ... preclinical and clinical stage compounds. The company advances the ...
Breaking Biology Technology:
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/9/2015)... Nov. 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced broader entry into the automotive market with a ... the pace of consumer electronics human interface innovation. Synaptics, ... ideal for the automotive industry and will be implemented ... Europe , Japan , ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
Breaking Biology News(10 mins):